Rekvina Labs Ltd
₹62.10▲ +0.61 (+0.99%)
VINRKLB·BSE·Healthcare
Market Cap
37.43 Cr
PE Ratio
-187.90
Volume
8,045
Day High - Low
62.10 - 60.20
52W High-Low
65.07 - 6.75
₹62.10▲ +0.61 (+0.99%)
Market Cap37.43 Cr
PE Ratio-187.90
Volume8,045
Day High - Low62.10 - 60.20
52W High-Low65.07 - 6.75
Rekvina Labs Ltd (VINRKLB): company summary
The company's annual revenue remained flat at ₹1 crore, while annual net profit continued to show a loss of ₹0 crore.
Rekvina Labs Ltd (VINRKLB) is a micro-cap Healthcare company valued at ₹37 crore operating in Pharmaceuticals on the NSE and BSE.
- Recent price move
- Rekvina Labs Ltd last traded at ₹62.1, modestly up 0.99% on the day.
- Financial performance
- The company's annual revenue remained flat at ₹1 crore, while annual net profit continued to show a loss of ₹0 crore. The latest quarter saw revenue stay at ₹1 crore, with net profit also remaining at ₹0 crore loss, matching the same quarter a year earlier.
- Valuation multiples
- A price-to-earnings ratio is not meaningful here because the company is loss-making; the stock trades at 16.77 times book value.
- Things to watch
- The company reported a net loss of ₹0 crore in its latest financial year, with no improvement in profitability. The net profit margin remains at -20.1%, indicating ongoing unprofitability.
- Where it stands
- The company continues to report a net loss of ₹0 crore, with no change in profitability over the past year. The net profit margin remains at -20.1%, highlighting the lack of profitability.
Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
DocStoX Score
4.4/10
Weak
Fair Value
Sign in to see
ROE
20.74%
Strong
P/E
-187.90x
Loss-making
Debt / Equity
—
Industry
Healthcare
Pharmaceuticals
Overall View
Mixed
Price performance
Day₹60.20
₹62.10
52W₹6.75
₹65.07
DocStoX take
Supported by growth (7.5) and momentum (7.5), but held back by valuation (0.0). Growth looks strong at 7.5, but that is offset by valuation at 0.0. We are calling it Mixed rather than resolving the conflict for you.
DocStoX score
Low confidence4.4
/10
Weak
Quality
Modest
ROE 20.7%
Valuation
Expensive
P/B 16.8× on assets (no earnings to value)
Growth
Strong
Revenue +45.4% 10Y CAGR
Risk
Moderate
D/E -1.20
Momentum
Strong
95% of 52-week range
At a glance
Market Cap
₹37 Cr
52W High / Low
₹65 / ₹7
Dividend Yield
0.00%
Promoter Holding
41.30%
EPS (TTM)
₹-0.42
Book Value
₹3.70
Key highlights
- Revenue compounding 45% a year
- Low leverage — D/E -1.20
- Capital works hard — ROCE 21%
- Loss-making — no meaningful P/E
- Loss-making in some of the last 5 years
4 Positives4 Watchouts
Growth
Financials
Technicals
Peers
News
Forecasts
About the company
More data
Filings, corporate actions and ownership detail — opened on demand.
More Healthcare stocks · Pharmaceuticals
Explore Rekvina Labs Ltd’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Rekvina Labs Ltd peers in Healthcare
Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.
Related tools & concepts
Value Rekvina Labs Ltd with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing